Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2020

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

iBio, Inc. (NYSE MKT: IBIO), is a global leader in plant-based biologics manufacturing. Its FastPharming System® combines automated hydroponics, vertical farming and glycan engineering technologies to increase speed-to-clinic of scalable, consistently high-quality monoclonal antibodies, antigens, bioinks and other recombinant proteins. iBio is leveraging its FastPharming Technologies to develop novel biopharmaceuticals for respiratory and fibrotic disease indications, among others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s FastGlycaneering Development Service includes an array of new glycosylation technologies for engineering high-performance recombinant proteins.

Investor Contact Information

Company

iBio Inc.
8800 HSC Pkwy
Bryan, TX 77807
T: 979-446-0027
ir@ibioinc.com

Investor Relations

Stephen Kilmer
T: 646-274-3580
skilmer@ibioinc.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com